Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Today, HC Wainwright reiterated its Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a price target of $60.00.
There are 7 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $34.6250 per share, a potential 77.75% upside.
Some recent analyst ratings include
- 11/1/2018-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had its Buy rating reiterated by HC Wainwright with a $60.00 price target
- 9/21/2018-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has coverage initiated with a Positive rating
- 8/7/2018-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has coverage initiated with a Hold ➝ Hold rating and $17.00 price target
- On 9/20/2018 Bros. Advisors Lp Baker, Director, bought 1,210,776 with an average share price of $18.70 per share and the total transaction amounting to $22,641,511.20.
- On 3/1/2018 Daniel B Soland, Director, bought 7,000 with an average share price of $23.91 per share and the total transaction amounting to $167,370.00.
- On 1/29/2018 Glenn Baity, EVP, sold 36,558 with an average share price of $32.39 per share and the total transaction amounting to $1,184,113.62.
- On 1/2/2018 Glenn Baity, EVP, sold 74,321 with an average share price of $30.14 per share and the total transaction amounting to $2,240,034.94.
- On 1/2/2018 Laura Brege, Director, sold 25,000 with an average share price of $30.06 per share and the total transaction amounting to $751,500.00.
- On 10/5/2017 Glenn Baity, EVP, sold 37,500 with an average share price of $40.91 per share and the total transaction amounting to $1,534,125.00.
- On 8/30/2017 Glenn Baity, EVP, sold 26,507 with an average share price of $34.87 per share and the total transaction amounting to $924,299.09.
About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 19,48 −1,61 7,63 % with shares trading hands.